<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Hepatol Commun</journal-id><journal-id journal-id-type="iso-abbrev">Hepatol Commun</journal-id><journal-id journal-id-type="pmc-domain-id">3345</journal-id><journal-id journal-id-type="pmc-domain">hep</journal-id><journal-id journal-id-type="publisher-id">HC9</journal-id><journal-title-group><journal-title>Hepatology Communications</journal-title></journal-title-group><issn pub-type="epub">2471-254X</issn><publisher><publisher-name>Wolters Kluwer Health</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10234461</article-id><article-id pub-id-type="pmcid-ver">PMC10234461.1</article-id><article-id pub-id-type="pmcaid">10234461</article-id><article-id pub-id-type="pmcaiid">10234461</article-id><article-id pub-id-type="pmid">37255351</article-id><article-id pub-id-type="doi">10.1097/HC9.0000000000000163</article-id><article-id pub-id-type="publisher-id">HEP4-23-0273</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Correspondence</subject></subj-group></article-categories><title-group><article-title>All perspectives need to be accounted for when determining the effectiveness of therapies for alcohol use disorder</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8184-1546</contrib-id><name name-style="western"><surname>Rogal</surname><given-names initials="SS">Shari S.</given-names></name><xref rid="aff1" ref-type="aff">1</xref><email>shari.rogal@va.gov</email></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0265-8100</contrib-id><name name-style="western"><surname>Chaudhari</surname><given-names initials="RB">Rahul B.</given-names></name><xref rid="aff2" ref-type="aff">2</xref><email>rahul.chaudhari@vcuhealth.org</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Morgan</surname><given-names initials="TR">Timothy R.</given-names></name><xref rid="aff3" ref-type="aff">3</xref><email>timothy.morgan@va.gov</email></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Bajaj</surname><given-names initials="JS">Jasmohan S.</given-names></name><email>jasmohan.bajaj@vcuhealth.org</email><xref rid="aff2" ref-type="aff">2</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>Department of Medicine, Pittsburgh VA Medical Center and University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA</aff><aff id="aff2">
<label>2</label>Department of Medicine, Richmond VA Medical Center and Virginia Commonwealth University, Richmond, Virginia, USA</aff><aff id="aff3">
<label>3</label>Department of Medicine, Long Beach VA Medical Center, Long Beach, California, USA</aff><author-notes><corresp><bold>Correspondence</bold> Jasmohan S. Bajaj, Richmond VA Medical Center and Virginia Commonwealth University, Department of Medicine, 1201 Broad Rock Boulevard, Richmond, Virginia 23249,USA. Email: <email>jasmohan.bajaj@vcuhealth.org</email></corresp></author-notes><pub-date pub-type="collection"><month>6</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>31</day><month>5</month><year>2023</year></pub-date><volume>7</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">435908</issue-id><elocation-id>e0163</elocation-id><history><date date-type="received"><day>30</day><month>3</month><year>2023</year></date><date date-type="accepted"><day>30</day><month>3</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>31</day><month>05</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>02</day><month>06</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-06-02 10:25:21.060"><day>02</day><month>06</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-Non Commercial-No Derivatives License 4.0</ext-link> (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="hc9-7-e0163.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="hc9-7-e0163.pdf"/><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta><custom-meta><meta-name>Read-along</meta-name><meta-value>YES</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>We were pleased to read Rabiee et al.&#8217;s<xref rid="R1" ref-type="bibr">1</xref> study of alcohol use disorder (AUD) treatment in high-risk veterans with liver disease. This is a critically important issue, and the report draws attention to the need to increase evidence-based AUD treatments in liver clinics, especially in those with cirrhosis.<xref rid="R2" ref-type="bibr">2</xref>
</p><p>Implementation science and health equity frameworks challenge us to tackle evidence-to-practice gaps, such as these with active strategies to address implementation barriers at the patient, provider, and system levels, which are often difficult to parse out. The Veterans Affairs (VA) system has many important implementation facilitators, including a national medical record system, national clinical reminders, and an engaged proactive group of more than 200 hepatology clinicians who work on quality improvement projects.<xref rid="R3" ref-type="bibr">3</xref> This system is also an excellent example of data transparency, engaged efforts to improve the quality of care, and a learning health care system approach to addressing evidence-to-practice gaps using state-of-the-art implementation methods, including pharmacological treatments for AUD.<xref rid="R4" ref-type="bibr">4</xref>
</p><p>VA outperforms non-VA on several measures, including medications for alcohol use disorder (MAUD). In fact, our prior study also found that a non-VA system had had half the MAUD rate (2% in a non-VA high-volume quarternary liver transplant center vs 4% in VA).<xref rid="R5" ref-type="bibr">5</xref> The finding that MAUD increased over time in the paper by Rabiee et al<xref rid="R1" ref-type="bibr">1</xref> is encouraging and likely reflects national VA efforts to increase MAUD. Implementation science offers frameworks to consider the many barriers to implementation that requires a deeper study of the circumstances surrounding the AUD. These include the outer setting (eg, national alcohol policies and pricing, and insurance coverage of MAUD), inner setting barriers (eg, the clinic infrastructure), characteristics of individuals (eg, patient and provider self-efficacy), the characteristics of the innovation (eg, the relative advantage of MAUD versus behavioral therapy), and the implementation process (eg, strategies in place to address barriers).<xref rid="R2" ref-type="bibr">2</xref> Thus, there are likely many causes of low MAUD adoption in and out of the VA and among patients with and without liver disease.</p><p>The AUD treatment ideally includes a shared decision&#8211;making process, wherein patients are offered both evidence-based behavioral and pharmacological treatments. We found that many times patients declined offers for AUD treatment in a chart review study.<xref rid="R6" ref-type="bibr">6</xref> Likewise, our non-VA study found strong evidence of provider stigma in these conversations and their notes, which may translate into patient decline.<xref rid="R5" ref-type="bibr">5</xref> These findings emphasize the need for future work toward increasing AUD-related care, which starts with capturing data from all ends of the patient, caregiver, system, and societal spectrum.</p></body><back><ack><sec sec-type="COI-statement"><title>CONFLICTS OF INTEREST</title><p>The authors have no conflicts to report.</p></sec></ack><fn-group><fn fn-type="abbr"><p>
<bold>Abbreviation:</bold> AUD, alcohol use disorder.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rabiee</surname><given-names>A</given-names></name><name name-style="western"><surname>Mahmud</surname><given-names>N</given-names></name><name name-style="western"><surname>Falker</surname><given-names>C</given-names></name><name name-style="western"><surname>Garcia-Tsao</surname><given-names>G</given-names></name><name name-style="western"><surname>Taddei</surname><given-names>T</given-names></name><name name-style="western"><surname>Kaplan</surname><given-names>DE</given-names></name></person-group>. <article-title>Medications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis</article-title>. <source>Hepatol Commun</source>. <year>2023</year>;<volume>7</volume>:<fpage>e0093</fpage>.<pub-id pub-id-type="pmid">36972386</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/HC9.0000000000000093</pub-id><pub-id pub-id-type="pmcid">PMC10043587</pub-id></mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mellinger</surname><given-names>JL</given-names></name><name name-style="western"><surname>Scott Winder</surname><given-names>G</given-names></name><name name-style="western"><surname>DeJonckheere</surname><given-names>M</given-names></name><name name-style="western"><surname>Fontana</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Volk</surname><given-names>ML</given-names></name><name name-style="western"><surname>Lok</surname><given-names>ASF</given-names></name><etal/></person-group>. <article-title>Misconceptions, preferences and barriers to alcohol use disorder treatment in alcohol-related cirrhosis</article-title>. <source>J Subst Abuse Treat</source>. <year>2018</year>;<volume>91</volume>:<fpage>20</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">29910011</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsat.2018.05.003</pub-id></mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yakovchenko</surname><given-names>V</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>TR</given-names></name><name name-style="western"><surname>Miech</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Neely</surname><given-names>B</given-names></name><name name-style="western"><surname>Lamorte</surname><given-names>C</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Core implementation strategies for improving cirrhosis care in the Veterans Health Administration</article-title>. <source>Hepatology</source>. <year>2022</year>;<volume>76</volume>:<fpage>404</fpage>&#8211;<lpage>17</lpage>.<pub-id pub-id-type="pmid">35124820</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep.32395</pub-id><pub-id pub-id-type="pmcid">PMC9288973</pub-id></mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harris</surname><given-names>AHS</given-names></name><name name-style="western"><surname>Brown</surname><given-names>R</given-names></name><name name-style="western"><surname>Dawes</surname><given-names>M</given-names></name><name name-style="western"><surname>Dieperink</surname><given-names>E</given-names></name><name name-style="western"><surname>Myrick</surname><given-names>DH</given-names></name><name name-style="western"><surname>Gerould</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Effects of a multifaceted implementation intervention to increase utilization of pharmacological treatments for alcohol use disorders in the US Veterans Health Administration</article-title>. <source>J Subst Abuse Treat</source>. <year>2017</year>;<volume>82</volume>:<fpage>107</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="pmid">29021108</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsat.2017.09.002</pub-id></mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alexandre</surname><given-names>W</given-names></name><name name-style="western"><surname>Muhammad</surname><given-names>H</given-names></name><name name-style="western"><surname>Agbalajobi</surname><given-names>O</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G</given-names></name><name name-style="western"><surname>Gmelin</surname><given-names>T</given-names></name><name name-style="western"><surname>Adejumo</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Alcohol treatment discussions and clinical outcomes among patients with alcohol-related cirrhosis</article-title>. <source>BMC Gastroenterol</source>. <year>2023</year>;<volume>23</volume>:<fpage>29</fpage>.<pub-id pub-id-type="pmid">36732709</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12876-023-02656-z</pub-id><pub-id pub-id-type="pmcid">PMC9896743</pub-id></mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaudhari</surname><given-names>RB</given-names></name><name name-style="western"><surname>Duong</surname><given-names>N</given-names></name><name name-style="western"><surname>Shrestha</surname><given-names>S</given-names></name><name name-style="western"><surname>Badal</surname><given-names>B</given-names></name><name name-style="western"><surname>Dharia</surname><given-names>N</given-names></name><name name-style="western"><surname>Robalino Gonzaga</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Patient and provider-level factors that underlie alcohol use disorder treatment offer and acceptance in veterans with cirrhosis</article-title>. <source>Alcohol Clin Exp Res</source>. <year>2022</year>;<volume>46</volume>:<fpage>809</fpage>&#8211;<lpage>14</lpage>.<pub-id pub-id-type="pmid">35312086</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/acer.14809</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>